Company profile
Helixion Therapeutics
Personalized cancer vaccines at software speed.
- Industry
- Biotechnology Research
- Employees
- 1
- Headquarters
- Vancouver, BC
- Founded
- 2025
- LinkedIn followers
- 58
- Office locations
- 1
Helixion Therapeutics company summary
Helixion Therapeutics is a company in the Biotechnology Research industry, headquartered in Vancouver, BC, founded in 2025. On LinkedIn the company has around 1 employees and 58 followers.
What technology does Helixion Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Helixion Therapeutics
Helixion Therapeutics Helixion Therapeutics is a Vancouver-based biotechnology company building AI-powered personalized cancer vaccines. Our platform, Elyra, converts patient tumor genomic data into ranked neoantigen candidates for personalized mRNA vaccine design — in days, not months, at a fraction of the cost of conventional approaches. The Problem We Are Solving Personalized cancer vaccines work by identifying mutations in a patient's tumor that produce protein fragments — called neoantigens — which the immune system can recognize and attack. A tumor may carry hundreds of mutations, but only a handful will produce neoantigens capable of triggering a meaningful immune response. A vaccine can carry only 10 to 20 candidates. Choosing the right ones is a computational problem, and the current clinical standard has not kept pace with what the science now tells us about immunogenicity. The dominant tool in clinical neoantigen prediction ranks candidates primarily by binding affinity — how strongly a peptide binds to the patient's immune presentation molecules. But binding affinity is only one of several factors that determine whether a neoantigen will actually trigger an immune response. Is the gene active in the patient's tumor? If not, the mutation cannot produce a neoantigen, regardless of binding strength. Does the mutation make the peptide look sufficiently foreign compared to the normal version? Is the mutation positioned where T cells can recognize it? Published research has established that these factors matter significantly. The TESLA consortium — 36 research groups with experimentally confirmed immunogenicity labels — identified five key parameters governing neoantigen immunogenicity. Yet in clinical practice, most vaccine trials still rank by binding affinity alone. Elyra: Our AI Neoantigen Engine Elyra is a Gradient Boosted Machine scoring model trained on 18,000 cancer-specific peptides from public immunogenicity databases. It integrates five biologica
Where is Helixion Therapeutics located?
Helixion Therapeutics lists 1 location.
Compare companies similar to Helixion Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Helixion Therapeutics helixiontx.com | Biotechnology Research | 1 | 2025 | Vancouver, BC |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Helixion Therapeutics
What does Helixion Therapeutics do?
Helixion Therapeutics Helixion Therapeutics is a Vancouver-based biotechnology company building AI-powered personalized cancer vaccines. Our platform, Elyra, converts patient tumor genomic data into ranked neoantigen candidates for personalized mRNA vaccine design — in days, not months, at a fraction of the cost of conventional approaches. The Problem We Are Solving Personalized cancer vaccines work by identifying mutations in a patient's tumor that produce protein fragments — called neoantigens — which the immune system can recognize and attack. A tumor may carry hundreds of mutations, but only a handful will produce neoantigens capable of triggering a meaningful immune response. A vaccine can carry only 10 to 20 candidates. Choosing the right ones is a computational problem, and the current clinical standard has not kept pace with what the science now tells us about immunogenicity. The dominant tool in clinical neoantigen prediction ranks candidates primarily by binding affinity — how strongly a peptide binds to the patient's immune presentation molecules. But binding affinity is only one of several factors that determine whether a neoantigen will actually trigger an immune response. Is the gene active in the patient's tumor? If not, the mutation cannot produce a neoantigen, regardless of binding strength. Does the mutation make the peptide look sufficiently foreign compared to the normal version? Is the mutation positioned where T cells can recognize it? Published research has established that these factors matter significantly. The TESLA consortium — 36 research groups with experimentally confirmed immunogenicity labels — identified five key parameters governing neoantigen immunogenicity. Yet in clinical practice, most vaccine trials still rank by binding affinity alone. Elyra: Our AI Neoantigen Engine Elyra is a Gradient Boosted Machine scoring model trained on 18,000 cancer-specific peptides from public immunogenicity databases. It integrates five biologica
How many employees does Helixion Therapeutics have?
Helixion Therapeutics has around 1 employees on LinkedIn.
Where is Helixion Therapeutics headquartered?
Helixion Therapeutics is headquartered in Vancouver, BC.
When was Helixion Therapeutics founded?
Helixion Therapeutics was founded in 2025.
Build a lead list from companies like Helixion Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.